Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immuron Limited ( (AU:IMC) ) just unveiled an announcement.
Immuron Limited has announced a significant increase in sales for its over-the-counter immune supplement, Travelan, which targets pathogenic bacteria in the gastrointestinal tract. The company reported a 49% increase in global sales, reaching AUD $7.3 million for FY25, with notable growth in both the Australian and North American markets. This growth supports Immuron’s strategy to establish Travelan as a travel essential and highlights its strong market positioning, particularly in Australia where it is one of the fastest-growing pharmacy brands.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
Average Trading Volume: 78,544
Technical Sentiment Signal: Sell
Current Market Cap: A$14.97M
Find detailed analytics on IMC stock on TipRanks’ Stock Analysis page.